All In MedTech

Device Trial Radar · NCT04123535

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

5

Actual

Start

Jan 23, 2020

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Matthew BucknorAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Focused Ultrasound Foundation; InSightec-TxSonics
First posted
Oct 11, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.

Conditions

  • Undifferentiated Pleomorphic Sarcoma

Interventions

  • ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)Device

    The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with reported Device-Related Adverse EventsTime frame: Approximately 1-4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.